Phase 3 Readoutnegative~month

Phase 3 Topline: Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastati

Indication
Non-small Cell Lung Cancer Metastatic

Other upcoming events for SNY

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Eff
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Eff
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Modified Double-blind, Multi-center Study of the Immunogenicity and Safety of an Investig
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Multinational, Randomized, Double-blind, Double-dummy, Active-comparator Stu
Phase 3 ReadoutPhase 3 Topline: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B,

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Randomized, Open-label, Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated, Metastati — SNY Phase 3 Readout | BioSniper